Stewart Varney introduces Biogen's experimental Alzheimer's drug. Taylor Riggs explains that the compelling Phase 2 study demonstrated robust biomarker impact and cognitive benefits, confirming a meaningful slowdown in the decline of early-stage Alzheimer's. Lou Basenese emphasizes the significant progress in neurodegenerative diseases.